SUPERNOVA is a large Phase III global trial providing the only efficacy data in immunocompromised patients
The award recognizes powerful science–industry collaborations for social good
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
Cresset’s new India site will support the growing demands of Cresset’s APAC customer base
225Ac-PSMA-Trillium is an investigational next-generation PSMA-targeted alpha therapy with potential to treat patients with advanced metastatic prostate cancer
Outlook 2024 remains flat CER sales growth and CORE EBITDA margin of high 20s
EBITDA before special items falls 1.3 percent to € 4.41 billion
Sevelamer Carbonate Tablets approval consolidates the company's position in the Sevelamer segment
These devices instantly detect various arrhythmias, including atrial fibrillation (Afib), bradycardia, tachycardia, and more
The company has posted net profit of Rs.615.82 crores for the Financial Year ended March 31, 2024
Subscribe To Our Newsletter & Stay Updated
